Correlation Between Acumen Pharmaceuticals and Coya Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Acumen Pharmaceuticals and Coya Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acumen Pharmaceuticals and Coya Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Acumen Pharmaceuticals and Coya Therapeutics, Common, you can compare the effects of market volatilities on Acumen Pharmaceuticals and Coya Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acumen Pharmaceuticals with a short position of Coya Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acumen Pharmaceuticals and Coya Therapeutics,.

Diversification Opportunities for Acumen Pharmaceuticals and Coya Therapeutics,

0.6
  Correlation Coefficient

Poor diversification

The 3 months correlation between Acumen and Coya is 0.6. Overlapping area represents the amount of risk that can be diversified away by holding Acumen Pharmaceuticals and Coya Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Coya Therapeutics, Common and Acumen Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acumen Pharmaceuticals are associated (or correlated) with Coya Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Coya Therapeutics, Common has no effect on the direction of Acumen Pharmaceuticals i.e., Acumen Pharmaceuticals and Coya Therapeutics, go up and down completely randomly.

Pair Corralation between Acumen Pharmaceuticals and Coya Therapeutics,

Given the investment horizon of 90 days Acumen Pharmaceuticals is expected to under-perform the Coya Therapeutics,. In addition to that, Acumen Pharmaceuticals is 1.07 times more volatile than Coya Therapeutics, Common. It trades about -0.28 of its total potential returns per unit of risk. Coya Therapeutics, Common is currently generating about -0.19 per unit of volatility. If you would invest  608.00  in Coya Therapeutics, Common on September 22, 2024 and sell it today you would lose (84.00) from holding Coya Therapeutics, Common or give up 13.82% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Acumen Pharmaceuticals  vs.  Coya Therapeutics, Common

 Performance 
       Timeline  
Acumen Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Acumen Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Coya Therapeutics, Common 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Coya Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Coya Therapeutics, is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Acumen Pharmaceuticals and Coya Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Acumen Pharmaceuticals and Coya Therapeutics,

The main advantage of trading using opposite Acumen Pharmaceuticals and Coya Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acumen Pharmaceuticals position performs unexpectedly, Coya Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Coya Therapeutics, will offset losses from the drop in Coya Therapeutics,'s long position.
The idea behind Acumen Pharmaceuticals and Coya Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Other Complementary Tools

ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance